280 related articles for article (PubMed ID: 23478748)
1. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.
Smesny S; Milleit B; Hipler UC; Milleit C; Schäfer MR; Klier CM; Holub M; Holzer I; Berger GE; Otto M; Nenadic I; Berk M; McGorry PD; Sauer H; Amminger GP
Mol Psychiatry; 2014 Mar; 19(3):317-24. PubMed ID: 23478748
[TBL] [Abstract][Full Text] [Related]
2. [Membrane lipids in schizophrenia and early phases of psychosis: Potential biomarkers and therapeutic targets?].
Frajerman A; Kebir O; Chaumette B; Tessier C; Lamazière A; Nuss P; Krebs MO
Encephale; 2020 Jun; 46(3):209-216. PubMed ID: 32151446
[TBL] [Abstract][Full Text] [Related]
3. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.
Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR
Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167
[TBL] [Abstract][Full Text] [Related]
4. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
[TBL] [Abstract][Full Text] [Related]
5. Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids.
Mossaheb N; Papageorgiou K; Schäfer MR; Becker J; Schloegelhofer M; Amminger GP
Early Interv Psychiatry; 2018 Feb; 12(1):30-36. PubMed ID: 26362578
[TBL] [Abstract][Full Text] [Related]
6. Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study.
Berger ME; Smesny S; Kim SW; Davey CG; Rice S; Sarnyai Z; Schlögelhofer M; Schäfer MR; Berk M; McGorry PD; Amminger GP
Transl Psychiatry; 2017 Aug; 7(8):e1220. PubMed ID: 28850110
[TBL] [Abstract][Full Text] [Related]
7. Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis.
Lavoie S; Schäfer MR; Whitford TJ; Benninger F; Feucht M; Klier CM; Yuen HP; Pantelis C; McGorry PD; Amminger GP
Schizophr Res; 2012 Jul; 138(2-3):206-11. PubMed ID: 22520856
[TBL] [Abstract][Full Text] [Related]
8. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
[TBL] [Abstract][Full Text] [Related]
9. Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.
Smesny S; Milleit B; Schaefer MR; Hesse J; Schlögelhofer M; Langbein K; Hipler UC; Berger M; Cotter DR; Sauer H; McGorry PD; Amminger GP
Schizophr Res; 2017 Oct; 188():110-117. PubMed ID: 28126360
[TBL] [Abstract][Full Text] [Related]
10. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.
Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP
Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065
[TBL] [Abstract][Full Text] [Related]
11. Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial.
Armando M; De Crescenzo F; Vicari S; Digilio MC; Pontillo M; Papaleo F; Amminger GP
Early Interv Psychiatry; 2016 Oct; 10(5):390-6. PubMed ID: 25345540
[TBL] [Abstract][Full Text] [Related]
12. Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial.
Phelan N; O'Connor A; Kyaw Tun T; Correia N; Boran G; Roche HM; Gibney J
Am J Clin Nutr; 2011 Mar; 93(3):652-62. PubMed ID: 21270384
[TBL] [Abstract][Full Text] [Related]
13. Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study.
Kim SW; Jhon M; Kim JM; Smesny S; Rice S; Berk M; Klier CM; McGorry PD; Schäfer MR; Amminger GP
PLoS One; 2016; 11(3):e0151417. PubMed ID: 26963912
[TBL] [Abstract][Full Text] [Related]
14. Polyunsaturated fatty acids in emerging psychosis: a safer alternative?
Schlögelhofer M; Amminger GP; Schaefer MR; Fusar-Poli P; Smesny S; McGorry P; Berger G; Mossaheb N
Early Interv Psychiatry; 2014 Aug; 8(3):199-208. PubMed ID: 24861004
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms.
Hsu MC; Huang YS; Ouyang WC
Lipids Health Dis; 2020 Jul; 19(1):159. PubMed ID: 32620164
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial.
Amminger GP; Chanen AM; Ohmann S; Klier CM; Mossaheb N; Bechdolf A; Nelson B; Thompson A; McGorry PD; Yung AR; Schäfer MR
Can J Psychiatry; 2013 Jul; 58(7):402-8. PubMed ID: 23870722
[TBL] [Abstract][Full Text] [Related]
17. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
[TBL] [Abstract][Full Text] [Related]
18. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?
Mossaheb N; Schäfer MR; Schlögelhofer M; Klier CM; Cotton SM; McGorry PD; Amminger GP
Schizophr Res; 2013 Aug; 148(1-3):163-7. PubMed ID: 23778032
[TBL] [Abstract][Full Text] [Related]
19. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis.
Alqarni A; Mitchell TW; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Berger M; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Meyer BJ; Amminger GP
Schizophr Res; 2020 Dec; 226():52-60. PubMed ID: 31606244
[TBL] [Abstract][Full Text] [Related]
20. Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls.
Rice SM; Schäfer MR; Klier C; Mossaheb N; Vijayakumar N; Amminger GP
Psychiatry Res; 2015 Jul; 228(1):174-6. PubMed ID: 25979466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
